"Polycythemia Vera" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
| Descriptor ID |
D011087
|
| MeSH Number(s) |
C04.588.448.200.500 C15.378.190.250.500 C15.378.190.636.753 C15.378.400.200.500
|
| Concept/Terms |
Polycythemia Vera- Polycythemia Vera
- Primary Polycythemia
- Polycythemia, Primary
- Polycythemias, Primary
- Primary Polycythemias
- Polycythemia Rubra Vera
- Polycythemia Rubra Veras
- Vera, Polycythemia Rubra
- Veras, Polycythemia Rubra
- Polycythemia Ruba Vera
- Polycythemia Ruba Veras
- Ruba Vera, Polycythemia
- Ruba Veras, Polycythemia
- Vera, Polycythemia Ruba
- Veras, Polycythemia Ruba
- Osler-Vaquez Disease
- Disease, Osler-Vaquez
- Osler Vaquez Disease
- Erythremia
- Erythremias
|
Below are MeSH descriptors whose meaning is more general than "Polycythemia Vera".
Below are MeSH descriptors whose meaning is more specific than "Polycythemia Vera".
This graph shows the total number of publications written about "Polycythemia Vera" by people in this website by year, and whether "Polycythemia Vera" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2005 | 3 | 0 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 4 | 1 | 5 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 2 | 3 |
| 2011 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 3 | 1 | 4 |
| 2015 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Polycythemia Vera" by people in Profiles.
-
Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety. Cancer. 2025 Jan 01; 131(1):e35661.
-
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature. Expert Opin Pharmacother. 2024 Jul; 25(10):1391-1404.
-
Polycythemia vera: past, present and future. Leuk Lymphoma. 2024 Nov; 65(11):1552-1564.
-
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. N Engl J Med. 2024 Feb 22; 390(8):723-735.
-
Moving toward disease modification in polycythemia vera. Blood. 2023 11 30; 142(22):1859-1870.
-
Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. Blood. 2023 04 27; 141(17):2127-2140.
-
Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023 04 20; 141(16):1909-1921.
-
Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera. Expert Rev Hematol. 2023 05; 16(5):305-316.
-
Downregulated KLF2 in polycythemia vera and essential thrombocythemia induces prothrombotic gene expression. Blood Adv. 2023 03 14; 7(5):712-717.
-
Clinicopathologic characteristics of myeloproliferative neoplasms with JAK2 exon 12 mutation. Leuk Res. 2023 04; 127:107033.